Amgen is a leader in biotechnology-based human therapeutics... Show more
AMGN saw its Momentum Indicator move below the 0 level on August 28, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned negative. In of the 72 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on August 27, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
AMGN moved below its 50-day moving average on August 25, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AMGN crossed bearishly below the 50-day moving average on August 29, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AMGN entered a downward trend on September 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.040) is normal, around the industry mean (9.666). P/E Ratio (22.599) is within average values for comparable stocks, (23.899). Projected Growth (PEG Ratio) (0.891) is also within normal values, averaging (1.753). Dividend Yield (0.034) settles around the average of (0.028) among similar stocks. P/S Ratio (4.283) is also within normal values, averaging (3.444).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
KOLD | 38.19 | 0.22 | +0.58% |
ProShares UltraShort Bloomberg Natrl Gas | |||
BCHI | 29.61 | 0.06 | +0.19% |
GMO Beyond China ETF | |||
SOXX | 255.64 | 0.45 | +0.18% |
iShares Semiconductor ETF | |||
FTQI | 20.50 | 0.03 | +0.15% |
First Trust Nasdaq BuyWrite Income ETF | |||
ITDB | 32.79 | -0.04 | -0.11% |
iShares LifePath Target Date 2030 ETF |
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with ABBV. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then ABBV could also see price increases.
Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
---|---|---|---|---|
AMGN | 100% | -2.24% | ||
ABBV - AMGN | 55% Loosely correlated | -0.85% | ||
GILD - AMGN | 49% Loosely correlated | -2.81% | ||
NVS - AMGN | 49% Loosely correlated | -2.80% | ||
PFE - AMGN | 46% Loosely correlated | -3.98% | ||
MRK - AMGN | 44% Loosely correlated | -2.75% | ||
More |